The average cost of Rexulti with commercial insurance is almost $26, but the savings card can provide the medication for free ...

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodegenerative disorder.

Analysts have suggested that approval for AAD could swell sales of Rexulti by $500 million to $1 billion, a big step up for a drug which currently ... At the Veeva Commercial Summit in Madrid ...